28
total announcements
ALIVUS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹16,550 Cr
P/E (TTM)
27.5
P/E (Forward)
21.5
EPS (TTM)
₹49.03
52W Low
₹819.00
52W High
₹1,493.80
Dividend Yield
0.37%
Beta
0.07
Price / Book
5.0
Debt / Equity
1.7
Revenue (TTM)
₹2,590 Cr
Gross Margin
59.42%
Operating Margin
29.84%
Alivus Life Sciences Limited
Alivus Life Sciences Limited has received an order from the Central Goods & Service Tax Department for FY 2020-21 and FY 2021-22, with an amount of Rs. 25,61,400, along with penalty and interest, but the company claims no material impact on its financial operations.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has acquired a 9.21% stake in Torrent Urja 19 Private Limited, a special purpose vehicle formed for setting up solar or other renewable energy projects, to comply with regulatory requirements for being a captive user under Indian electricity laws.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has incorporated a wholly owned subsidiary company in Brazil, Alivus Life Sciences Do Brasil Ltda., with an authorized capital of R$ 500,000.00 and 100% shareholding by the Company.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about the schedule of an investor/analyst meeting to be held on September 17, 2026, at the Kotak Healthcare Forum 2026 in Mumbai.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has held its 15th Annual General Meeting (AGM) on September 8, 2026, through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The meeting was attended by 38 shareholders, and the requisite quorum was present. The Chairman and Managing Director addressed the members, highlighting the company's strong financial performance, future growth strategy, and commitment to creating long-term value for shareholders and stakeholders.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about the schedule of investor/analyst meetings to be conducted on September 10 and 11, 2026, in Mumbai.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about the schedule of meet with investors/analysts on September 9, 2026, in Mumbai. The meetings will be held in-person and are one-on-one with Breakout Capital, UTI, Kotak Mutual Fund, and Param Capital.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about the schedule of investor/analyst meetings to be conducted from August 28, 2026, to September 2, 2026, in virtual and in-person formats.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. The acquisition will enable Alivus to leverage its core portfolio selectively into advanced formulation development and expand its global customer base in the generic pharmaceutical segment.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced the acquisition of 76% stake in IQGEN-X Pharma Private Limited for approximately INR 9.12 crores, subject to customary adjustments.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about the schedule of investor/analyst meetings to be conducted on August 18-19, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting information.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has submitted its Business Responsibility & Sustainability Report for FY 2025-26, as per SEBI regulations.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting (AGM) to be held on September 8, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about a scheduled investor/analyst meeting on August 12, 2026, to be attended by the company's representatives, including SBI Mutual Fund.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about a scheduled investor/analyst meeting on August 12, 2026, in Mumbai, which may be subject to change.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about Transcript of earnings call held on July 31, 2026. The company reported revenues of INR640 crores, a 6.4% year-on-year growth during the quarter, driven by strong growth of 26.5% year-on-year in non-GPL business.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange about a copy of newspaper publication regarding intimation of 15th AGM.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has announced the record date for the purpose of dividend as September 1, 2026, and the 15th Annual General Meeting will be held on September 8, 2026.
Alivus Life Sciences Limited
Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 08, 2026. The company has recommended a final dividend of Rs.5.00 per Equity share of Rs.2 each for the financial year ended March 31, 2026.